Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Ethical Drug Sales 1.1%, in October: Crecon Report
December 10, 2014
- Efficacy of Lenalidomide in Treatment-Naïve Patients with Multiple Myeloma Confirmed in Domestic PII Study: Celgene
December 10, 2014
- Takeda, Monash University of Australia to Collaborate in Gastroenterology Field
December 10, 2014
- Data Suggest Potential Feasibility of Ixazomib as Maintenance Therapy for Multiple Myeloma: Takeda
December 9, 2014
- Eisai’s Fycompa Cuts Tonic-Clonic Seizure Frequency by 76.5%
December 9, 2014
- Adcetris Significantly Extends PFS in Post-Transplant Hodgkin lymphoma Patients: Takeda
December 9, 2014
- Abilify Maintena Approved for Use in Acutely Relapsed Adults with Schizophrenia in the US: Otsuka, Lundbeck
December 9, 2014
- April-September Sales Drop 21.5% for Major Long-Listed Products
December 8, 2014
- Daiichi Sankyo to Harness Ties with Cardiologists in Lixiana Promotion
December 8, 2014
- Pfizer Japan Launches CML Drug Bosulif
December 8, 2014
- Zenyaku Kogyo to Initiate Preclinical Study for Nucleic Acid Medicine for Psoriasis as Early as Next Year
December 8, 2014
- COPD Drug Ultibro Launched in UK
December 8, 2014
- CareNet, EP-PharmaLine to Jointly Provide Online, Phone Detailing Services
December 8, 2014
- Nipro Sets Up New Sales Firm in Malaysia
December 8, 2014
- Nippon Chemiphar to Set Up Plant in Vietnam, Operation Launch Slated in 2018
December 5, 2014
- First-Line Xalkori Shows Superiority to Chemotherapy in ALK-Positive NSCLC: Pfizer
December 5, 2014
- Chiome Bioscience Succeeds in Producing Antibody to Ebola
December 5, 2014
- Asahi Kasei Pharma Licenses Teribone to South Korea’s Dong-A ST
December 5, 2014
- M3 Poised to More than Double Revenue from Clinical Trial Services
December 5, 2014
- Safety Confirmed in Preliminary Results from PI Study of Preventive AIDS Vaccine: Dnavec
December 4, 2014
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…